Get the Weekly Intelligence Brief — top committee picks every Sunday.

GH vs HSIC

Guardant Health, Inc. vs Henry Schein — AI-powered side-by-side comparison
GH
Guardant Health, Inc.
61
Buy
VS
HSIC
Henry Schein
67
Buy
MetricGHHSIC
AI Score 61 67
Price $165.06 $89.16
P/E Ratio -47.30× 25.77×
ROE 419.2% 12.3%
Revenue Growth YoY
Gross Margin 65.0% 30.3%
Debt / Equity -7.61× 1.21×
Dividend Yield 0.0% 0.0%
RSI (14) 60.9 59.4
Beta 1.586 0.808
Expected Upside +0.8%

AI Committee View

Current Innellis committee reasoning for GH versus HSIC.
HSIC leads by 6 points.

HSIC scores 67/100 (Buy) versus GH at 61/100 (Buy).

GH Committee View
75% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 20.0% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • Bollinger bandwidth of 20.0% signals elevated volatility — Risk
HSIC Committee View
75% agreement
4 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GH Full Analysis HSIC Full Analysis